Inspur Launches New AI Servers to Support Latest NVIDIA A100 PCIe Gen 4 at ISC20
22.6.2020 10:07:00 EEST | Business Wire | Press release
Inspur, a leading data center and AI full-stack solutions provider, releases NF5468M6 and NF5468A5 AI servers supporting the latest NVIDIA A100 PCIe Gen 4 GPU at ISC High Performance 2020. It will provide AI users around the world with the ultimate AI computing platform with superior performance and flexibility.
Thanks to its agile and strong product design and development capabilities, Inspur is one of the first in the industry to support the NVIDIA A100 Tensor Core GPU and build up a comprehensive and competitive next-generation AI computing platform. The A100 GPU brings unprecedented versatility by accelerating a full range of precisions—from FP32 to FP16 to INT8 and all the way down to INT4. This includes the new TF32 precision, which works like FP32 while providing 20X higher FLOPS for AI without requiring any code change. In addition, the NVIDIA A100 offers multi-instance GPU technology, which enables a single GPU to be partitioned into seven hardware-isolated instances to work on multiple networks simultaneously. At present, Inspur’s two new products-NF5488M5-D and NF5488A5 with the NVIDIA A100 have taken the lead in mass production.
The newly released NF5468M6 and NF5468A5 present many innovative designs and strike a balance between superior performance and flexibility, which well meets increasingly complex and diverse AI computing needs. NF5468M6 and NF5468A5 can offer superb computing performance for high-performance computing and cloud application scenarios.
NF5468M6 and NF5468A5 accommodate eight double-width A100 PCIe cards in a 4U chassis. Both support the latest PCIe Gen4 of 64GB/s bi-directional bandwidth, delivering a 100% increase in bandwidth compared to PCIe Gen3 with the same power consumption. Its superior performance will meet the requirements of the most complex challenges in data science, high-performance computing, and artificial intelligence. Besides, 40GB of HBM2 memory increases memory bandwidth by 70% to 1.6TB/s, allowing users to train larger deep learning models. The unique NVIDIA NVLink bridge design can provide P2P performance of up to 600GB/s between two GPUs, resulting in significant increases in training efficiency
Furthermore, another two leading AI servers of Inspur, NF5468M5 and NF5280M5, also support NVIDIA A100 PCIe Gen 4.
As the world’s leading AI server manufacturer, Inspur offers an extensive range of AI products, and works closely with AI customers to improve AI application performance in different scenarios such as voice, semantic, image, video, and search.
About Inspur
Inspur is a leading provider of data center infrastructure, cloud computing, and AI solutions, ranking among the world’s top 3 server manufacturers. Through engineering and innovation, Inspur delivers cutting-edge computing hardware design and extensive product offerings to address important technology arenas like open computing, cloud data center, AI, and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle specific workloads and real-world challenges. To learn more, please go to www.inspursystems.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005207/en/
Contact information
Fiona Liu
Liuxuan01@inspur.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 16:26:00 EET | Press release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at an adjusted PBR of 0.40x, representing a severe 60% discount to its Comprehensive Equity under IFRS17. Align Partners identifies inefficient capital allocation and a lack of independent governance oversight as primary drivers of this persistent undervaluation. The letter notes that DBI’s Return on Required Capital (ROR) of 21.2% significantly lags behind domestic and global peers, reflecting a historical focus on top-line growth over risk-adjusted profitability. This is exacerbated by a passive payout policy and
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 14:00:00 EET | Press release
Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/en/ “You can now potentially study intracellular target engagement for any protein in live cells,” says M
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 14:00:00 EET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 12:37:00 EET | Press release
Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming from outside Hong Kong. The HKTDC presents the world’s largest one-s
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 12:30:00 EET | Press release
FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integrate FX Spot+ and EBS Market liquidity into their existing FlexFX workflows, accelerating time to market and r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
